Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aires Pharmaceuticals Inc.

Division of Mast Therapeutics Inc./AIres Pharmaceuticals Inc.
www.airespharma.com

Latest From Zogenix Inc.

Opana Withdrawal Request Builds On US FDA Actions On Palladone, OxyContin

Earlier withdrawals of Purdue’s Palladone and original OxyContin create precedent for request that Endo’s Opana ER come off market due to risk of abuse; former chief counsel sees agency's move as ‘tip of the iceberg’ on opioid safety actions.

Drug Safety Post Market Regulation & Studies

Gottlieb Closing In On Confirmation Despite Senate Concern On Opioids

US FDA commissioner nominee clears procedural hurdle as agency's opioid policy remains a charged political issue.

FDA Leadership

Opioid Policy At US FDA: Gottlieb Seeks More Activist Role To Combat Abuse

‘Dramatic action’ needed to curb opioid epidemic, commissioner-nominee says, including potentially a cross-center approach to evaluating drugs and devices for pain, and new nomenclature for formulations currently labeled as abuse deterrent.

FDA Drug Safety

Takeda Targets Severe Epilepsies In Ovid Alliance

Takeda is continuing apace with smaller targeted alliances despite its big Ariad acquisition, this time linking with a private US venture for the global development of a novel drug for serious pediatric epilepsies, in a move that aligns with the Japanese firm's pursuit of R&D externalization.

Commercial Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Nasal
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Mast Therapeutics Inc.
  • Savara Inc.
  • Senior Management
  • Wendy S Johnson, Pres. & CEO
    Julie A Crawford, Dir., Fin.
    Ed Parsley, CMO
  • Contact Info
  • Aires Pharmaceuticals Inc.
    Phone: (858) 366-9670
    4365 Executive Dr.
    Ste. 1500
    San Diego, CA 92121
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register